Organ Preservation without Extreme Hypothermia Using an Oxygent™ Supplemented Perfusate

Abstract

All methods of organ preservation depend upon hypothermia to depress metabolism during storage. Yet, hypothermia may represent the rate-limiting factor in organ preservation. A new perfusate has been developed which supports organ preservation without extreme hypothermia. The perfusate consists of a complex fluid supplemented with an oxygen carrying perfluorocarbon emulsion, Oxygent (Alliance Pharmaceutical Corp,). The perfusate was used to preserve canine kidney autografts using pulsatile preservation at 32 degrees C and static storage at 25 degrees C. Upon autografting the dogs produced urine within minutes of reperfusion. These results indicate the new perfusate may have significant potential in organ preservation without extreme hypothermia.

Normothermic machine perfusion of the kidney: better conditioning and repair?

“…Brasile et al . were the first to develop an acellular normothermic solution based on a perfluorocarbon (PFC) emulsion (Perflubron) and enriched tissue culture‐like medium containing essential and nonessential amino acids, lipids and carbohydrates (Table ). They have published numerous studies using canine, porcine and discarded human kidneys using this pressure‐controlled device .…”

Aerobic Preservation of Organs Using a New Perflubron/Lecithin Emulsion Stabilized by Molecular Dowels

“…45 min of warm ischemia and 8 hr of in situ Oxygent We noted no statistically significant difference in the (perflubron/EYP emulsion) perfusion at 25-32ЊC [18]. hepatic function parameters measured: AST, ALT, and…”

Blood monitoring of perfluorocarbon compounds (F-tert-butylcyclohexane, perfluoromethyldecalin and perfluorodecalin) by headspace-gas chromatography-tandem mass spectrometry

“…Benefits of PFCs in clinical medicine were shown in animal models and humans with applications including respiratory distress syndrome [1], pulmonary drug administrations, radiologic imaging and diagnosis through development as Sonazoid s [2,3] or as artificial red blood cell substitution [4]. PFCs (mainly pure solutions) as oxygen therapeutics can be implemented in biomedical applications such as tissular ischaemia, liquid ventilation, organ preservation [5,6], cardiology (myocardial ischaemia), acute haemorrhage, perioperative haemodilution (cardiovascular and orthopaedic surgery) [7][8][9] or as a heavy tamponade during vitreo-retinal surgery [10][11][12][13]. Concerning PFC emulsion, they are not available for human usage in Europe or North America today.…”